Elusive Therapeutic Effect of PCSK9 Inhibitors on Lipoprotein(a) Levels

被引：10

作者：

Sbrana, Francesco ^{[1
]}

Bigazzi, Federico ^{[1
]}

Dal Pino, Beatrice ^{[1
]}

Toma, Maddalena ^{[1
]}

Ripoli, Andrea ^{[2
]}

Sampietro, Tiziana ^{[1
]}

机构：

[1] Fdn Toscana Gabriele Monasterio, Lipoapheresis Unit, Reference Ctr Diag & Treatment Inherited Dyslipid, Pisa, Italy

[2] Fdn Toscana Gabriele Monasterio, Bioengn Dept, Pisa, Italy

来源：

THERAPEUTIC APHERESIS AND DIALYSIS | 2019年 / 23卷 / 04期

关键词：

APHERESIS; ANTIBODY;

D O I：

10.1111/1744-9987.12766

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：385 / 386

页数：2

共 7 条

[1] Discordant response of low-density lipoprotein cholesterol and lipoprotein(a) levels to monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9 [J].

Edmiston, Jonathan B. ;

Brooks, Nathan ;

Tavori, Nagai ;

Minnier, Jessica ;

Duell, Bart ;

Purnell, Jonathan Q. ;

Kaufman, Tina ;

Wojcik, Cezary ;

Voros, Szilard ;

Fazio, Sergio ;

Shapiro, Michael D. .

JOURNAL OF CLINICAL LIPIDOLOGY, 2017, 11 (03) :667-673

[2] Effect of Alirocumab, a Monoclonal Proprotein Convertase Subtilisin/Kexin 9 Antibody, on Lipoprotein(a) Concentrations (a Pooled Analysis of 150 mg Every Two Weeks Dosing from Phase 2 Trials) [J].

Gaudet, Daniel ;

Kereiakes, Dean J. ;

McKenney, James M. ;

Roth, Eli M. ;

Hanotin, Corinne ;

Gipe, Daniel ;

Du, Yunling ;

Ferrand, Anne-Catherine ;

Ginsberg, Henry N. ;

Stein, Evan A. .

AMERICAN JOURNAL OF CARDIOLOGY, 2014, 114 (05) :711-715

[3] How effectively will PCSK9 inhibitors allow retrieval of freedom from apheresis in cardiovascular high risk patients? - Estimates form a large single center [J].

Hohenstein, Bernd ;

Tselmin, Sergey ;

Bornstein, Stefan R. ;

Julius, Ulrich .

ATHEROSCLEROSIS SUPPLEMENTS, 2017, 30 :28-32

[4] Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial [J].

Moriarty, Patrick M. ;

Parhofer, Klaus G. ;

Babirak, Stephan P. ;

Cornier, Marc-Andre ;

Duell, P. Barton ;

Hohenstein, Bernd ;

Leebmann, Josef ;

Ramlow, Wolfgang ;

Schettler, Volker ;

Simha, Vinaya ;

Steinhagen-Thiessen, Elisabeth ;

Thompson, Paul D. ;

Vogt, Anja ;

von Stritzky, Berndt ;

Du, Yunling ;

Manvelian, Garen .

EUROPEAN HEART JOURNAL, 2016, 37 (48) :3588-3595

[5] Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145) [J].

Raal, Frederick J. ;

Giugliano, Robert P. ;

Sabatine, Marc S. ;

Koren, Michael J. ;

Langslet, Gisle ;

Bays, Harold ;

Blom, Dirk ;

Eriksson, Mats ;

Dent, Ricardo ;

Wasserman, Scott M. ;

Huang, Fannie ;

Xue, Allen ;

Albizem, Moetaz ;

Scott, Rob ;

Stein, Evan A. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 63 (13) :1278-1288

[6] Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease: Prospective 5 Years of Follow-Up and Apolipoprotein(a) Characterization [J].

Roeseler, Eberhard ;

Julius, Ulrich ;

Heigl, Franz ;

Spitthoever, Ralf ;

Heutling, Dennis ;

Breitenberger, Paul ;

Leebmann, Josef ;

Lehmacher, Walter ;

Kamstrup, Pia R. ;

Nordestgaard, Borge G. ;

Maerz, Winfried ;

Noureen, Asma ;

Schmidt, Konrad ;

Kronenberg, Florian ;

Heibges, Andreas ;

Klingel, Reinhard .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2016, 36 (09) :2019-2027

[7] A Test in Context: Lipoprotein(a) Diagnosis, Prognosis, Controversies, and Emerging Therapies [J].

Tsimikas, Sotirios .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (06) :692-711

← 1 →